Quick Summary — CNS scores higher on quality with 7.4/10 vs CXE's 1.7/10. CNS trades at $71.20 while CXE trades at $3.67. Both analyzed daily using SEC EDGAR data across 13 institutional models.
CNS scores higher with a 7.4/10 quality rating vs CXE's 1.7/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.
At $71.20, CNS trades +76.2% above its Bayesian DCF fair value of $16.96, while CXE at $3.67 trades +74.0% above its estimate of $0.95. CNS shows a wider gap between price and intrinsic value.
CNS earns a Quality of Company score of 7.4/10 compared to CXE's 1.7/10. This is a significant quality gap — the higher-scoring company demonstrates materially stronger fundamentals across profitability, growth consistency, and balance sheet health. The QOC score synthesizes 32 signals spanning profitability margins, revenue growth, free cash flow, capital allocation, and leverage.
Review the value trap analysis for both CNS and CXE to assess whether apparent undervaluation reflects genuine opportunity or hidden fundamental risk.
Both CNS and CXE operate in Asset Management, which has 448 stocks tracked by CirclFi. Same-industry comparisons provide the most direct insight into relative valuation since both companies face similar regulatory environments, market dynamics, and competitive pressures. Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN), and ensemble methods (CUCE).
11 hidden models compare CNS vs CXE differently — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more. Some may disagree with the 2 you see above.
Bloomberg Terminal: ~$2,000/mo · FactSet: ~$1,000/mo · CirclFi: $0.90/day
See All 13 Models — $0.90/dayWe don’t predict prices. We show you what 13 independent mathematical frameworks say a stock is worth — and let you decide.